Reuters logo
5 months ago
BRIEF-Novo's once-weekly semaglutide shows consistent bloodglucose reductions
April 3, 2017 / 7:00 AM / 5 months ago

BRIEF-Novo's once-weekly semaglutide shows consistent bloodglucose reductions

April 3 (Reuters) - Novo Nordisk

* Says once-weekly semaglutide demonstrated consistent bloodglucose reductions and weight loss regardless of background oral antidiabetic treatment

* Says findings from a post hoc analysis of the phase 3a SUSTAIN 2-4 trials demonstrated greater mean reductions in HbA1c and body weight with once-weekly semaglutide treatment compared to sitagliptin, exenatide extended release (ER) and insulin glargine U100 in adults with type 2 diabetes, across multiple background oral antidiabetic (OAD) treatment categories

* The results were presented at the Endocrine Society's 99th Annual Meeting and Expo (ENDO 2017) in Orlando, Florida in the United States Further company coverage: (Copenhagen newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below